---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-010378"
form_type: "8-K"
ticker: "ZIVO"
cik: "0001101026"
company_name: "Zivo Bioscience, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:21:13.997399+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zivo Bioscience granted Nasdaq extension to Nov 20, 2023 to regain equity compliance

## Summary
- Received deficiency notice on May 23, 2023 for stockholders' equity below $2.5M (Listing Rule 5550(b)).
- Nasdaq Hearings Panel held on July 13, 2023; extension granted until November 20, 2023.
- Extension conditioned on filing Form S-1 with SEC by October 5, 2023.
- Company intends to regain compliance but delisting risk remains; potential adverse effect on capital access.

## SEC filing metadata
- accession: 0001654954-23-010378
- form_type: 8-K
- ticker: ZIVO
- cik: 0001101026
- company_name: Zivo Bioscience, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1101026/000165495423010378/0001654954-23-010378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1101026/000165495423010378/zivo_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-010378
- JSON: https://secwatch.observer/filing/0001654954-23-010378.json
- Plain text: https://secwatch.observer/filing/0001654954-23-010378.txt

## Key facts
- Listing & Compliance Notices
  Zivo Bioscience, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5550(b)
  source text: August 4, 2023, the Company received a notification letter from the Nasdaq notifying the Company that the Panel has granted the Company’s request to provide an extension until November 20, 2023 (the “Exception Period”), to regain compliance with the Stockholders’ Equity Rule for continued listing on Nasdaq. The Panel further noted that the Exception Period for continued listing is subject to a filing of a registration statement on Form S-1 by the Company with the U.S. Securities and Exchange Commission (the “SEC”) on or before October 5, 2023. The Panel concluded that the Exception Period is
  evidence_url: https://www.sec.gov/Archives/edgar/data/1101026/000165495423010378/0001654954-23-010378-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.